Melflufen Is Safe and Effective in Patients with Alkylator-Refractory Disease
Fredrik Schjesvold gives his insights into the OCEAN trial, which investigates melflufen’s role in refractory multiple myeloma by comparing pomalidomide-dexamethasone with melflufen-dexamethasone in refractory cases.